Episurf — Regulatory Filings 2020

Jun 8, 2020

New European patent approval for Episurf Medical

The European patent office EPOhas announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled "System and method for creating a decision support material indicating damage to an anatomical joint", is within the area of 3D-based assessment of joint lesions, and complements the company's previously approved patents within that field.

"Episurf Medical's damage marking technology constitutes a central part of the Episealer® implant system as well as the Epioscopy® joint visualisation system. Our visualisation of joint damage, which includes AI-based 3D-modelling, is unique and we are building a strong patent protection around it", says Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.45 CEST on 8 June 2020.